New perspective on Immune Aging Biomarkers for Clinical Trials

How can we measure immune ageing in clinical trials?

In a new perspective of the Biomarkers of Aging Consortium together with XPRIZE Healthspan, published today in Nature Medicine, we discuss the current status and future directions.

There are lots of tools that work in a research lab, but multi-centre trials face distinct hurdles - such as logistics, standardisation, access to equipment, and many others. And: how do we even begin to quantify ageing of such a complex and dynamic system? Together with a group of contributors spanning experts across immunology, clinical trials, geroscience, and biomarkers, we set out to define key immune ageing terminology, define standardised criteria and evaluate existing candidates with them. There are some highly promising candidates, however what is also becoming increasingly clear is that we need:

• more data on longitudinal within-person variability
• measures that capture how well the immune system might respond to future infections or insults, and encapsulate immune resilience and allostasis.

You can read the full article here.